Magazine Article | February 7, 2018

Companies To Watch: Zavante

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Challenging drug resistance with a retooled antibiotic and a broad mechanism of action.

SNAPSHOT
Zavante has completed a pivotal Phase 2/3 trial of its lead broad-spectrum antibiotic drug, ZOLYD (fosfomycin injection), for treating complicated urinary tract infections (cUTI) and expects to fi le a new drug application for the product in mid-2018. Fosfomycin has a long history outside the U.S., but the company has recast the injectable to improve its pharmacokinetics and pharmacodynamics against acute infections in a hospital setting. ZOLYD has a unique mechanism of action and is targeted at GRAM-positive and GRAM-negative infections, including those caused by multidrug-resistant bacteria.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: